Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$286K Buy
5,184
+1
+0% +$54 0.1% 107
2025
Q4
$254K Buy
5,183
+1
+0% +$47 0.1% 112
2025
Q3
$224K Buy
+5,182
New +$202K 0.09% 116
2024
Q2
Sell
-4,850
Closed -$208K 97
2024
Q1
$208K Sell
4,850
-1,081
-18% -$44.6K 0.12% 93
2023
Q4
$220K Sell
5,931
-295
-5% -$10.6K 0.14% 90
2023
Q3
$226K Hold
6,226
0.15% 84
2023
Q2
$222K Sell
6,226
-321
-5% -$11.5K 0.15% 87
2023
Q1
$233K Hold
6,547
0.16% 88
2022
Q4
$230K Buy
+6,547
New +$218K 0.17% 85
2022
Q3
Sell
-7,015
Closed -$382K 93
2022
Q2
$382K Sell
7,015
-291
-4% -$16.1K 0.29% 69
2022
Q1
$398K Buy
7,306
+51
+0.7% +$2.77K 0.28% 72
2021
Q4
$400K Buy
+7,255
New +$377K 0.28% 70

Other funds holding GSK

Powers Advisory Group's GSK Position: Q1 2026 in Review

Powers Advisory Group increased its GSK (GSK) stake by 0.02% in Q1 2026, buying an estimated $54 and bringing the position to 5,184 shares worth $286K. The position accounts for 0.1% of the portfolio, ranked #107.

Powers Advisory Group first reported a position in GSK in Q4 2021 and has held it in 12 quarters since. The position peaked at $400K in Q4 2021. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Powers Advisory Group held 5,184 shares of GSK worth $286K as of Q1 2026.
  • Powers Advisory Group bought 1 GSK share in Q1 2026, an estimated $54.
  • GSK made up 0.1% of Powers Advisory Group's portfolio in Q1 2026, its #107 holding.
  • Powers Advisory Group first reported a position in GSK in Q4 2021 and has held it in 12 quarters since.
  • Powers Advisory Group's GSK position peaked at $400K in Q4 2021.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Powers Advisory Group's 13F filing for Q1 2026, filed 21 Apr 2026.